Time Required to Dissolve Urate Deposits
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Oct 31, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called ReViGore40, is studying how long it takes for urate deposits, which are the crystals that cause gout, to dissolve in patients when their urate levels are kept very low. Gout can cause painful swelling in the joints, especially in the feet and knees. The researchers want to understand not only the average time it takes for these deposits to completely dissolve but also what factors might affect this time, such as a person's health history or genetics.
To be eligible for this trial, participants must be at least 18 years old and diagnosed with gout. They should have urate levels higher than 60 mg/L and a certain score on ultrasound scans that shows the presence of crystals in their joints. However, people currently taking medication to lower urate levels or those with serious health conditions like cancer or heart disease cannot participate. If you join this study, you will have regular ultrasound scans to monitor the progress of the treatment and help researchers learn more about gout and its treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age over 18 years
- • Gout according to the ACR/Eular 2015 criteria
- • SUA levels greater than 60 mg/L
- • US score (MTP1s, knees) ≥2/24
- • Informed consent Dated and signed voluntarily
- Exclusion Criteria:
- • Ongoing urate lowering therapy
- • Severe and uncontrolled diseases such as cancer, cardiovascular or neurovegetative diseases
- • Pregnant or breast-feeding women
- • No affiliation to the French National Social Security System
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported